Citation 77838

MIMAKI,Y: NAKAMURA,O: SASHIDA,Y: NIKAIDO,T: OHIMOTO,T:. (1995). STEROIDAL SAPONINS FROM THE BULBS OF TRITELEIA LACTEA AND THEIR INHIBITORY ACTIVITY ON CYCLIC AMP PHOSPHODIESTERASE.. 38(5)

Citation Details

TitleSTEROIDAL SAPONINS FROM THE BULBS OF TRITELEIA LACTEA AND THEIR INHIBITORY ACTIVITY ON CYCLIC AMP PHOSPHODIESTERASE.
AuthorsMIMAKI,Y: NAKAMURA,O: SASHIDA,Y: NIKAIDO,T: OHIMOTO,T:
Year1995
Volume38
Issue5

Summary

Year: 1995

Journal: Unknown

Organisms and Their Experiments (1)

Triteleia lactea (LILIACEAE)

Experiment #Pharmacology TypeWorktypesCompoundResults
1Not specified
ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
DIOSGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-BETA-D-GLUCOPYRANOSIDE]
None
2
CYCLIC AMP PHOSPHODIESTERASE INHIBITION
PHARMACOLOGY OF COMPOUND - IN VITRO
DIOSGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-BETA-D-GLUCOPYRANOSIDE]
WEAK ACTIVITY
3Not specified
ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
PENNOGENIN-3-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)-BETA-D-GLUCOPYRANOSIDE]
None
4Not specified
ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
DIOSCIN
None
5
CYCLIC AMP PHOSPHODIESTERASE INHIBITION
PHARMACOLOGY OF COMPOUND - IN VITRO
PENNOGENIN-3-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)-BETA-D-GLUCOPYRANOSIDE]
WEAK ACTIVITY
6
CYCLIC AMP PHOSPHODIESTERASE INHIBITION
PHARMACOLOGY OF COMPOUND - IN VITRO
DIOSCIN
WEAK ACTIVITY
7Not specified
ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
PENNOGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[ALPHA-L-RHAMNOPYRANOSYL(1-4)-BETA-D-GLUCOPYRANOSIDE}
None
8Not specified
ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
DIOSGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[BETA-D-GLUCOPYRANOSYL(1-3)]-BETA-D-GLUCOPYRANOSIDE]
None
9
CYCLIC AMP PHOSPHODIESTERASE INHIBITION
PHARMACOLOGY OF COMPOUND - IN VITRO
PENNOGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[ALPHA-L-RHAMNOPYRANOSYL(1-4)-BETA-D-GLUCOPYRANOSIDE}
WEAK ACTIVITY
10
CYCLIC AMP PHOSPHODIESTERASE INHIBITION
PHARMACOLOGY OF COMPOUND - IN VITRO
DIOSGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[BETA-D-GLUCOPYRANOSYL(1-3)]-BETA-D-GLUCOPYRANOSIDE]
ACTIVE
11Not specified
ISOLATION AND IDENTIFICATION OFQUANTITATIVE DATA
PENNOGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[BETA-D-GLUCOPYRANOSYL(1-3)]-BETA-D-GLUCOPYRANOSIDE]
None
12Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
DIOSGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[BETA-D-GALACTOPYRANOSYL(1-3)]-BETA-D-GLUCOPYRANOSIDE]
None
13
CYCLIC AMP PHOSPHODIESTERASE INHIBITION
PHARMACOLOGY OF COMPOUND - IN VITRO
PENNOGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[BETA-D-GLUCOPYRANOSYL(1-3)]-BETA-D-GLUCOPYRANOSIDE]
WEAK ACTIVITY
14
CYCLIC AMP PHOSPHODIESTERASE INHIBITION
PHARMACOLOGY OF COMPOUND - IN VITRO
DIOSGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[BETA-D-GALACTOPYRANOSYL(1-3)]-BETA-D-GLUCOPYRANOSIDE]
WEAK ACTIVITY
15Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
PENNOGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[BETA-D-GALACTOPYRANOSYL(1-3)-]BETA-D-GLUCOPYRANOSIDE]
None
16Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
NUATIGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[ALPHA-L-RHAMNOPYRANOSYL(1-4)]-BETA-D-GLUCOPYRANOSIDE]
None
17
CYCLIC AMP PHOSPHODIESTERASE INHIBITION
PHARMACOLOGY OF COMPOUND - IN VITRO
PENNOGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[BETA-D-GALACTOPYRANOSYL(1-3)-]BETA-D-GLUCOPYRANOSIDE]
WEAK ACTIVITY
18
CYCLIC AMP PHOSPHODIESTERASE INHIBITION
PHARMACOLOGY OF COMPOUND - IN VITRO
NUATIGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-[ALPHA-L-RHAMNOPYRANOSYL(1-4)]-BETA-D-GLUCOPYRANOSIDE]
WEAK ACTIVITY
19Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
GITOGENIN-3-O-[ALPHA-L-RHAMNOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE]
None
20Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
TIGOGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE]
None
21
CYCLIC AMP PHOSPHODIESTERASE INHIBITION
PHARMACOLOGY OF COMPOUND - IN VITRO
GITOGENIN-3-O-[ALPHA-L-RHAMNOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE]
WEAK ACTIVITY
22
CYCLIC AMP PHOSPHODIESTERASE INHIBITION
PHARMACOLOGY OF COMPOUND - IN VITRO
TIGOGENIN-3-O-[O-ALPHA-L-RHAMNOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE]
WEAK ACTIVITY
23Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
GITOGENIN-3-O-[BETA-D-GLUCOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE]
None
24Not specified
MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORQUANTITATIVE DATAISOLATION OF A COMPOUND WITH NOVEL STRUCTURE
SPIROST-25(27)-ENE-2-ALPHA-3-BETA-DIOL-3-O-[O-BETA-D-GLUCOPYRANOSYL(1-3)-O-BETA-D-GLCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE]
None
25
CYCLIC AMP PHOSPHODIESTERASE INHIBITION
PHARMACOLOGY OF COMPOUND - IN VITRO
GITOGENIN-3-O-[BETA-D-GLUCOPYRANOSYL(1-3)-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE]
ACTIVE
26
CYCLIC AMP PHOSPHODIESTERASE INHIBITION
PHARMACOLOGY OF COMPOUND - IN VITRO
SPIROST-25(27)-ENE-2-ALPHA-3-BETA-DIOL-3-O-[O-BETA-D-GLUCOPYRANOSYL(1-3)-O-BETA-D-GLCOPYRANOSYL(1-2)-O-[BETA-D-XYLOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-BETA-D-GALACTOPYRANOSIDE]
ACTIVE
Show SPARQL Queries (1)